Anti-SET-alpha, clone 5F4D9

Protein SET (UniProt Q01105; also known as HLA-DR-associated protein II, IGAAD, Inhibitor of granzyme A-activated DNase, PHAPII, I-2PP2A, Phosphatase 2A inhibitor I2PP2A, TAF-I, Template-activating factor I) is encoded by the SET gene (Gene ID 6418) in human. Protein SET (patient “SE translocation”) adopted its name when it was originally identified ia leukemia study in 1992. SET interacts with signaling pathways that promote normal cell growth and proliferation, as well as tumorigenesis and metastasis. SET protein inhibits PP2A by enhancing lyase activity of P450c17, a substrate for PP2A when it is Ser- and Thr-phosphorylated. Alternative splicings result in multiple SET isoforms, including SET-alpha (TAF-I alpha) and SET-beta (TAF-I beta), where the N-terminal 37-amino acid sequence in Set-α is replaced with a different sequence of a shorter length in Set-β. Both Set-α and Set-β are predominantly localized in the nucleus, but differ in their expression levels among various cell and tissue types. Set-β is predominant in the brain relative to Set-α, whereas the opposite pattern was observed in tissues such as the spleen.

Clone 5F4D9 recognizes an epitope sequence specific to spliced isoform SET-alpha (TAF-I alpha) of human protein SET (UniProt Q01105-1). The epitope sequence is not present in SET-beta (TAF-I beta) or any other human protein SET spliced isoforms reported by UniProt.

Epitope: Near N-terminus.

KLH-conjugated linear peptide corresponding to a sequence near the N-terminus of human SET-alpha.

Anti-Set-alpha, clone 5F4D9 is an antibody against Set-alpha for use in Western Blotting.

Research Category
Neuroscience

Research Sub Category
Signaling Neuroscience

Western Blotting Analysis: 0.5 µg/mL from a representative lot detected SET-alpha in 10 µg of PC3 human prostate cancer cell lysate.
Western Blotting Analysis: 2.0 µg/mL from a representative lot specifically detected SET-alpha, but not SET-beta in Ramos human Burkitt′s lymphoma cell lysate (Courtesy of M. P. Vitek, Ph.D. Dr. Vitek is an employee and stockholder in Oncotide Pharmaceuticals, Inc. and a faculty member of Duke University Medical Center. Matters of potential personal and institutional conflict of interest are managed by the Duke University Medical Center Conflict of Interest Committee).

Evaluated by Western Blotting in DU145 cell lysate.

Western Blotting Analysis: 0.5 µg/mL of this antibody detected SET-alpha in 10 µg of DU145 human prostate cancer cell lysate.

~38 kDa observed. Band size appears larger than the calculated molecular weight of 33.36 kDa (Met1 removed) due to posttranslational modification (acetylation and/or phosphorylation).

Format: Purified

Protein G purified.

Purified mouse monoclonal IgG1κ antibody in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.

Stable for 1 year at 2-8°C from date of receipt.

Concentration: Please refer to lot specific datasheet.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.